HUP0204370A3 - Use of pyrimidine endothelin antagonists for preparation of veterinary compositions - Google Patents

Use of pyrimidine endothelin antagonists for preparation of veterinary compositions

Info

Publication number
HUP0204370A3
HUP0204370A3 HU0204370A HUP0204370A HUP0204370A3 HU P0204370 A3 HUP0204370 A3 HU P0204370A3 HU 0204370 A HU0204370 A HU 0204370A HU P0204370 A HUP0204370 A HU P0204370A HU P0204370 A3 HUP0204370 A3 HU P0204370A3
Authority
HU
Hungary
Prior art keywords
pyrimidine
preparation
veterinary compositions
endothelin antagonists
endothelin
Prior art date
Application number
HU0204370A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HUP0204370A2 publication Critical patent/HUP0204370A2/hu
Publication of HUP0204370A3 publication Critical patent/HUP0204370A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
HU0204370A 2000-02-11 2001-02-06 Use of pyrimidine endothelin antagonists for preparation of veterinary compositions HUP0204370A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003234.2A GB0003234D0 (en) 2000-02-11 2000-02-11 Method of treatment
PCT/IB2001/000142 WO2001058882A1 (en) 2000-02-11 2001-02-06 Use of pyrimidine endothelin antagonists in companion animals

Publications (2)

Publication Number Publication Date
HUP0204370A2 HUP0204370A2 (en) 2003-05-28
HUP0204370A3 true HUP0204370A3 (en) 2003-07-28

Family

ID=9885465

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204370A HUP0204370A3 (en) 2000-02-11 2001-02-06 Use of pyrimidine endothelin antagonists for preparation of veterinary compositions

Country Status (17)

Country Link
EP (1) EP1254120B1 (hu)
JP (1) JP2003528050A (hu)
KR (1) KR20020075791A (hu)
AT (1) ATE271042T1 (hu)
AU (1) AU3043601A (hu)
CA (1) CA2398007A1 (hu)
DE (1) DE60104283T2 (hu)
DK (1) DK1254120T3 (hu)
ES (1) ES2222975T3 (hu)
GB (1) GB0003234D0 (hu)
HU (1) HUP0204370A3 (hu)
IL (1) IL150488A0 (hu)
NZ (1) NZ519002A (hu)
PT (1) PT1254120E (hu)
TR (1) TR200401815T4 (hu)
WO (1) WO2001058882A1 (hu)
ZA (1) ZA200206343B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647660B2 (en) 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
EP1874130A4 (en) * 2005-04-19 2009-04-29 Hills Pet Nutrition Inc METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING NURSE DISEASES
JP5637608B2 (ja) * 2010-02-25 2014-12-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 高親和性化合物の結合定数を求めるための方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882719B1 (en) * 1995-12-20 2001-05-16 Yamanouchi Pharmaceutical Co. Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
WO1998057938A1 (fr) * 1997-06-19 1998-12-23 Yamanouchi Pharmaceutical Co., Ltd. Derives d'alcanesulfonamide inferieur substitue et composition pharmaceutique les contenant

Also Published As

Publication number Publication date
HUP0204370A2 (en) 2003-05-28
DE60104283D1 (de) 2004-08-19
ES2222975T3 (es) 2005-02-16
WO2001058882A1 (en) 2001-08-16
DK1254120T3 (da) 2004-10-04
ATE271042T1 (de) 2004-07-15
CA2398007A1 (en) 2001-08-16
AU3043601A (en) 2001-08-20
DE60104283T2 (de) 2004-11-18
PT1254120E (pt) 2004-10-29
JP2003528050A (ja) 2003-09-24
EP1254120A1 (en) 2002-11-06
NZ519002A (en) 2004-06-25
KR20020075791A (ko) 2002-10-05
EP1254120B1 (en) 2004-07-14
ZA200206343B (en) 2003-08-08
TR200401815T4 (tr) 2004-08-23
GB0003234D0 (en) 2000-04-05
IL150488A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
HUP0301654A2 (en) Novel n-pyrimidinyl-sulfamides, their use as endothelin receptor antagonists and pharmaceutical compositions containing them
HUP0102160A3 (en) Use of alpha-keto enamine derivatives as ingredients
AU5945801A (en) Opoid antagonist compositions and dosage forms
AU6448101A (en) Novel compositions of minoxidil
HK1060056A1 (en) Pharmaceutical composition and kit comprising receptor tyrosine kinase inhibitors and angiogenesis inhibitors
EP1417180A4 (en) PREPARATION OF AMINO-PRIMIDINE COMPOUNDS
HUP0600605A2 (en) Urea substituted imidazoquinoline ethers, pharmaceutical compositions containing them and intermediates
HUP0302337A3 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
IL185461A0 (en) Pyrimidine compounds and their use
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
IL151369A (en) Use of tgf-beta antagonist for the preparation of pharmaceuticals
HUP0302382A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
EP1361872A4 (en) NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS
AU2002352476A8 (en) Urea derivatives and their use as vanilloid receptor antagonists
AU2790502A (en) Pyrimidine derivatives and their use as neuropeptide y receptor ligands
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
AU3070702A (en) Stabilized inteferon compositions
HUP0302003A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0301317A3 (en) Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions
HUP0303005A3 (en) Pharmaceutical compositions comprising pyrazolo[4,3-d]pyrimidines or thienopyrimidines and endothelin receptor antagonists
HUP0303045A3 (en) Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0302614A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
HUP0200080A3 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists and pharmaceutical compositions containing the compounds
ITMI20000378A0 (it) Uso di composti (per)fluoropolieterei come additivi in formulazioni